Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer
Portfolio Pulse from Vandana Singh
Novartis AG has released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy for advanced gastroenteropancreatic neuroendocrine tumors. The study met its primary endpoint of improvement in progression-free survival and the key secondary endpoint of objective response rate. No new or unexpected safety findings were observed. Morgan Stanley analyst Vincent Meunier upgraded Novartis from Underweight to Equal-Weight.
September 25, 2023 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' successful Phase 3 trial and the upgrade from Morgan Stanley could positively impact the company's stock in the short term.
The successful Phase 3 trial indicates that Novartis' Lutathera is effective and safe, which could increase the company's revenue if the product is approved and commercialized. Additionally, the upgrade from Morgan Stanley could attract more investors to the company, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100